news – Page 109

Unlocking Prognostic and Therapeutic Insights in Breast Cancer Through Whole-Genome Sequencing Linked With Mortality Data

By MedXY 10/15/2025

This retrospective UK study reveals that integrating whole-genome sequencing with clinical and mortality data enhances prognostication and identifies therapeutic targets in breast cancer, particularly in ER-positive, HER2-negative subtypes.

news

全ゲノム配列解析と死亡データを連携して乳がんの予後と治療の洞察を解明

By MedXY 10/15/2025

この英国の後ろ向き研究では、全ゲノム配列解析を臨床情報と死亡データと統合することで、特にER陽性HER2陰性サブタイプの乳がんにおける予後予測と治療標的の同定が向上することが示されました。

news Oncology Respiratory

Retifanlimab Plus Chemotherapy Significantly Prolongs Survival in Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial

By MedXY 10/15/2025

The POD1UM-304 study demonstrated that adding the PD-1 inhibitor retifanlimab to platinum-based chemotherapy significantly improves overall survival in patients with first-line metastatic non-small-cell lung cancer, offering a new therapeutic option with manageable safety.

news Oncology Respiratory

Radiotherapy-Free Pembrolizumab Plus Chemotherapy Shows Promise for Locally Advanced NSCLC With High PD-L1 Expression

By MedXY 10/15/2025

The Evolution trial evaluated pembrolizumab combined with chemotherapy without radiotherapy in unresectable, locally advanced NSCLC patients with PD-L1 TPS ≥50%, showing a 2-year progression-free survival rate of 67% and manageable safety profile, suggesting a viable alternative treatment approach.

General Surgery news

Optimizing Mesh Weight to Reduce Recurrence Reoperations in Laparoscopic Inguinal Hernia Repair

By MedXY 10/15/2025

A Danish cohort study identifies that using mesh weighing 45-65 g/m² in laparoscopic inguinal hernia repair results in the lowest reoperation rate for recurrence, guiding surgical mesh selection for better patient outcomes.

Cardiology Hematology-Oncology news

Clonal Hematopoiesis in Older Adults: Implications for Cardiovascular Risk, Bleeding, and Aspirin Use

By MedXY 10/15/2025

This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for those with CHIP in primary prevention of cardiovascular events.

Family Medicine & Nutrition news Psychiatry

Comparative Effectiveness of PTSD Treatments in Primary Care: Insights from a Pragmatic Randomized Trial

By MedXY 10/15/2025

A pragmatic trial comparing SSRIs and written exposure therapy in primary care PTSD treatment found similar effectiveness initially; switching to SNRI was superior to WET augmentation for SSRI nonresponders.

news Psychiatry Public Health

Rising Trends in Stimulant Use Disorder Diagnoses Among Adolescent and Young Adult Medicaid Enrollees: Implications for Clinical Practice

By MedXY 10/15/2025

Stimulant use disorder diagnoses in young adult Medicaid enrollees have markedly increased from 2001 to 2020, especially for noncocaine psychostimulants, highlighting an urgent need for targeted interventions and evidence-based treatments amid rising overdose risks.

Dermatology Nephrology news

Enhancing Skin Cancer Surveillance in Solid Organ Transplant Recipients: Impact of the KP-SUNTRAC Risk-Based Program

By MedXY 10/15/2025

A retrospective cohort study demonstrates that implementation of KP-SUNTRAC increases targeted skin cancer screening and detection among high-risk solid organ transplant recipients without increasing health care utilization.

Hematology-Oncology news

Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma

By MedXY 10/14/2025

The TRIMM-2 study reveals that talquetamab plus daratumumab yields high response rates and durable disease control in relapsed/refractory multiple myeloma with manageable safety, offering a novel combination strategy for heavily pretreated patients.

Hematology-Oncology news Rheumatology

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study

By MedXY 10/14/2025

A retrospective study of 88 patients with genetically confirmed VEXAS syndrome reveals that azacitidine improves inflammatory symptoms, cytopenias, and reduces UBA1 mutant clone burden with an acceptable safety profile, supporting its use and need for prospective trials.

Cardiology news

Dual Versus Single Antiplatelet Therapy After Valve-in-Valve TAVI: Balancing Stroke Prevention and Bleeding Risk

By MedXY 10/14/2025

This study compares dual and single antiplatelet therapy after valve-in-valve transcatheter aortic valve implantation, finding dual therapy reduces stroke risk without increasing bleeding or valve deterioration at one year.

Hematology-Oncology news Oncology

Defining a Distinct Subtype of TP53-Mutated AML via BAP1 Loss: Implications for Targeted Therapy with BCL-xL Inhibitors

By MedXY 10/14/2025

Loss of the tumor suppressor BAP1 characterizes a unique subtype of TP53-mutated de novo acute myeloid leukemia (AML), correlating with poorer prognosis and erythroid lineage priming, while revealing vulnerability to BCL-xL inhibition as a promising therapeutic strategy.

Hematology-Oncology news Rheumatology

UBA6: A Novel Therapeutic Vulnerability in VEXAS Syndrome Unveiled by E1 Enzyme Dependency Profiling

By MedXY 10/14/2025

This study characterizes UBA1 mutation effects in VEXAS syndrome and identifies UBA6 as a compensatory enzyme and promising therapeutic target, highlighting selective inhibition to combat mutant hematopoietic clones.

Hematology-Oncology news Oncology

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming

By MedXY 10/14/2025

Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune evasion in multiple myeloma.

Hematology-Oncology Infectious Diseases news

Decoding Epstein-Barr Virus Genomic Alterations: Implications for Human Malignancies and Disease Pathogenesis

By MedXY 10/14/2025

A comprehensive genomic analysis of Epstein-Barr virus (EBV) reveals distinct single nucleotide and structural variations linked to various human diseases, especially hematological malignancies, highlighting viral mechanisms underlying pathogenesis and potential therapeutic targets.

Hematology-Oncology news

Enhancing Patient Experience in DLBCL: Insights from PROs and Clinician-Reported AEs in the Phase 3 POLARIX Trial

By MedXY 10/14/2025

The POLARIX trial demonstrates superior progression-free survival with Pola-R-CHP in untreated DLBCL, highlighting the utility of patient-reported outcomes alongside clinician-reported adverse events to capture symptom burden and quality of life comprehensively.

Hematology-Oncology news

Decoding Progression Risk in IgM-MGUS and Asymptomatic Waldenström Macroglobulinemia Through Genomic Profiling

By MedXY 10/14/2025

This article explores how genomic features differentiate stable from progressive asymptomatic Waldenström macroglobulinemia and IgM-MGUS, highlighting mutation burdens, specific gene alterations, and aneuploidy as prognostic markers for disease progression.

Hematology-Oncology news

Genetic Architecture of Myeloproliferative Neoplasm Subtypes: Uncovering a Novel Sex-Specific Association at CDH22/CD40

By MedXY 10/14/2025

A large genome-wide analysis identifies multiple genetic loci influencing MPN subtypes and reveals a female-specific variant at CDH22/CD40, enhancing understanding of disease heterogeneity and potential for personalized risk stratification.

Dermatology Hematology-Oncology news

Prognostic Markers and Survival Outcomes in Advanced Mycosis Fungoides and Sézary Syndrome: Insights from the Cutaneous Lymphoma International Consortium

By MedXY 10/14/2025

A large international study identified key prognostic markers affecting survival in advanced-stage mycosis fungoides and Sézary syndrome, enabling risk stratification and guiding clinical management.